Person: Gareth Hatch

The Short Report, May 6, 2020: AbCellera receives $175.6M for COVID-19 therapies; Canada contributes $850 million to global pandemic response; new “super angel” fund launches; and more

Vancouver-based AbCellera Biologics will receive up to $175.6 million from the federal Strategic Innovation Fund to fast-track antibody therapies against COVID-19. The funding will also go to build a first-of-its-kind antibody manufacturing facility over the next four years to help Canada respond to future pandemics. AbCellera has partnered with global biopharmaceutical company Eli Lilly to…